Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610195 | 1.00 | CREBBP (0.36) | CREBBPIRAK4HTR2ADRD3CASP3 | |
| SCHEMBL30610188 | 0.74 | IDO1 (0.42) | — | |
| SCHEMBL20580607 | 0.74 | IDO1 (0.42) | — | |
| SCHEMBL3608159 | 0.69 | CHEK1 (0.48) | CREBBPMAPK14 | |
| SCHEMBL12499174 | 0.68 | CREBBP (0.45) | CREBBPMAPK14 | |
| SCHEMBL15491013 | 0.68 | CREBBP (0.42) | CREBBPCYP11B2MAPK14 | |
| SCHEMBL17731756 | 0.64 | IDO1 (0.41) | — | |
| SCHEMBL31687246 | 0.61 | JAK1 (0.43) | DRD3TYK2KDM1ADRD2 | |
| SCHEMBL6433955 | 0.60 | TYR (0.45) | HTR2ADRD3DRD2 | |
| SCHEMBL50350 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111943890-B | Pharmaceutical compounds | 艾欧米制药有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| CN-111943890-A | Pharmaceutical compounds | 艾欧米制药有限公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-107108556-B | Pharmaceutical compounds | 艾欧米制药有限公司 | 2020-09-29 | — | — | CN | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10590086-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20180354908-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130738-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | CREBBP 4574/4885IRAK4 3137/4885HTR2A 511/4885 |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IDO1, TDO2, IDO2 | CREBBP 4574/4885IRAK4 3137/4885HTR2A 511/4885 |
| US-10590086-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | CREBBP 4574/4885IRAK4 3137/4885HTR2A 511/4885 |
| US-20180354908-A1 | PHARMACEUTICAL COMPOUND | IDO1, TDO2, IDO2 | CREBBP 4574/4885IRAK4 3137/4885HTR2A 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.